CagriSema 25% Weight Loss in Women Impresses but Post Hoc Payer Hurdles Remain

Novo Nordisk's CagriSema Shows Significant Weight Loss in Women

Novo Nordisk announced results from two post hoc analyses of the Phase 3 REDEFINE 1 trial, showing its investigational once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) was associated with significant weight loss in women with obesity or overweight. In an analysis of 2,309 women, CagriSema led to an average weight loss of 25.0% at week 68, compared to 3.0% with placebo. A second analysis of 1,902 women, categorized by menopausal status, demonstrated average weight loss of 26.7% in premenopausal, 24.8% in perimenopausal, and 23.1% in postmenopausal women, all statistically significant compared to placebo. The findings were presented at The Menopause Society 2026 Annual Meeting.

• In a post hoc analysis of 2,309 women with obesity or overweight from the REDEFINE 1 trial, treatment with CagriSema 2.4 mg / 2.4 mg resulted in an average body weight loss of 25.0% at week 68. This was significantly superior to the 3.0% weight loss observed in the placebo group (p<0.0001), highlighting CagriSema's substantial efficacy in this population and its potential for weight management.
• A separate post hoc analysis of 1,902 women demonstrated consistent and clinically meaningful weight loss across different menopausal stages. Premenopausal women experienced an average weight loss of 26.7%, perimenopausal women 24.8%, and postmenopausal women 23.1% at week 68, all showing statistical significance compared to placebo (p<0.0001). This suggests broad applicability regardless of reproductive stage.
• The safety profile of CagriSema in REDEFINE 1 showed that 5.9% of participants discontinued due to adverse events, primarily gastrointestinal (79.6% vs. 39.9% for placebo), including nausea (55% vs. 12.6%), constipation (30.7% vs. 11.6%), and vomiting (26.1% vs. 4.1%), which were mostly transient and mild-to-moderate. Novo Nordisk filed a New Drug Application with the U.S. FDA in December 2025 for CagriSema for weight management, with a decision expected in Q4 2026.

REDEFINE 1: CagriSema's Efficacy in Women with Obesity

Recent studies in overweight and obesity compare incretin-based therapies head-to-head and against placebo, focusing on percentage weight change, achievement of weight-reduction targets, and tolerability. Tirzepatide and CagriSema show the largest reductions among evaluated agents, with gastrointestinal events as the predominant safety signal.

CagriSema's Novel Dual Mechanism for Weight Management

CagriSema pairs once-weekly semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, with cagrilintide, a once-weekly amylin receptor agonist. Amylin is co-secreted with insulin from β pancreatic cells upon nutrient delivery to the small intestine as a satiety signal, acts upon sub-cortical homeostatic and hedonic brain regions, slows gastric emptying, and suppresses post-prandial glucagon responses to meals. AM833 (cagrilintide), an investigational novel long-acting acylated amylin analogue, acts as a non-selective amylin receptor. This calcitonin G protein-coupled receptor agonist can serve as an attractive novel treatment for obesity, resulting in reduction of food intake and significant weight loss in a dose-dependent manner. Cagrilintide is described as a Dual Amylin and Calcitonin Receptor Agonist (DACRA) derived from an amylin backbone, and the fixed-dose combination with semaglutide (CagriSema) is listed among dual/triple agonists including cagrilintide 2.4 mg/semaglutide 2.4 mg alongside tirzepatide, survodutide, mazdutide and retatrutide that have recently completed phase 3 trials for T2D or are currently in phase 3 clinical trials.

Efficacy and safety of this amylin-based approach were evaluated in a systematic review and meta-analysis of four RCTs encompassing 5425 participants that assessed Cagrilintide monotherapy or CagriSema versus placebo in adults with overweight or obesity. Cagrilintide monotherapy produced significant reductions in body weight (MD: -6.08%; MD: -5.89 kg) and blood pressure, without meaningful HbA1c improvement. CagriSema significantly reduced body weight (MD: -5.98%; MD: -4.68 kg), waist circumference (MD: -10.91 cm), systolic blood pressure, and HbA1c. Both treatments showed modest but statistically significant increases in adverse events, and substantial heterogeneity was observed across most outcomes.

CagriSema exemplifies the broader shift toward combinations of GLP-1 with other entero-pancreatic hormones (glucose-dependent insulinotropic polypeptide (GIP), glucagon and amylin) under development for T2D and obesity management. Tirzepatide is the first approved dual agonist (GLP-1/GIP) for T2D and obesity management, while dual-agonist (GLP-1/GIP and GLP-1/GCG) and tri-agonist (GLP-1/GIP/GCG) administration generally result in greater weight loss, reduction of blood sugar and lipid levels, restoration of tissue function, and improvement in whole-body substrate metabolism compared to when GLP-1R agonists are used alone. In this landscape, entero-pancreatic hormone-based treatments can result in ≥15% WL and euglycemia for many people with T2D, with tirzepatide enabling many to achieve ≥20% weight loss.

Addressing Unmet Needs in Women's Obesity Management

Recent literature frames obesity as a chronic, multisystem disease requiring lifelong management to reduce adiposity while preserving lean muscle and bone health. Key challenges include interindividual variability in response, gastrointestinal tolerability and adherence to GLP-1 receptor agonist therapy, and loss of skeletal muscle mass during rapid weight loss.

• Older adults at risk for sarcopenia and sarcopenic obesity: Concerns have emerged about potential loss of skeletal muscle mass with pharmacologic weight reduction, particularly in older adults at risk for sarcopenia, including nursing home residents age 65 years and older and community-dwelling adults older than 60 years, where sarcopenic obesity is characterized by concurrent obesity and muscle wasting and has a greater effect on metabolic disease than either obesity or sarcopenia alone.

• Children and adolescents with early-onset obesity: Childhood obesity affecting nearly one in five U.S. children, including preschoolers and adolescents, with severe obesity as the fastest-growing subcategory, is increasingly associated with metabolic diseases such as diabetes, dyslipidemia, and non-alcoholic fatty liver disease observed in adulthood, and with higher risk of metabolic syndrome components in those with overweight and sarcopenic obesity.

• Patients with obesity and type 1 diabetes and those in intensive cardiac rehabilitation: People with obesity and type 1 diabetes treated with liraglutide, semaglutide, or tirzepatide with 12-month changes in body weight, HbA1c, total tissue fat, fat mass, lean mass, and preservation of total bone mineral density, and patients enrolled in a structured Pritikin intensive cardiac rehabilitation program where GLP-1 RA use was evaluated for changes in skeletal muscle mass and fat mass by bioelectrical impedance analysis.

• Cancer survivors and individuals with malnutrition and sarcopenic obesity: Growing interest in GLP-1 medicines among cancer survivors with obesity, with potential negative impact especially in those with cancer cachexia or sarcopenic obesity and those undergoing anticancer treatments that often lead to weight loss, and in acute pancreatitis where sarcopenic obesity quantified by psoas muscle area to body mass index, and coexistence of malnutrition diagnosed using Global Leadership Initiative on Malnutrition criteria, synergistically exacerbates inflammation and poor outcomes.

• Maternal pregravid obesity and offspring metabolic health: Pregravid obesity and excessive gestational weight gain affecting fetal steroid hormone biosynthesis, fatty acid metabolism, and fetal immune ontogeny, with increased risk of offspring cardio-metabolic disease later in life and altered inflammatory mediators and immune cell populations demonstrated in cord blood, fetal spleen and lung.

CagriSema's Safety and Tolerability Profile in REDEFINE 1

Gastrointestinal adverse events are the dominant tolerability signal for glucagon-like peptide-1 receptor agonists (GLP-1RAs) and tirzepatide in obesity and overweight, with additional signals spanning biliary-pancreatic, ocular, and neuropsychiatric domains. Large-scale randomized trials, meta-analyses, and observational studies provide reassurance on renal outcomes and mortality while pharmacovigilance data continue to define rare ocular and psychiatric signals.

• Gastrointestinal tolerability and discontinuation: Nausea, vomiting, diarrhea, and constipation are the most common side effects, generally emerging during dose escalation and resolving over time. Accumulating evidence has identified additional complications including cholelithiasis, cholecystitis, gastroparesis, and bowel obstruction, which may warrant caution in susceptible individuals. In hidradenitis suppurativa patients with type 2 diabetes and/or obesity, nausea/vomiting risk was increased (HR: 1.31), and in a 6-month real-world tirzepatide study gastrointestinal adverse events were the most frequently reported but rarely led to treatment discontinuation, with discontinuation in 20% of patients.

• Biliary-mediated pancreatic signal: Meta-analyses of randomized controlled trials demonstrate no statistically significant independent association between GLP-1 RA use and acute pancreatitis (MH-OR 1.24 [0.94, 1.64]; P = .13). Real-world data identifies a transient increase in risk during the first 6 months of treatment (HR 1.340; 95% CI, 1.239-1.449; P = .019), proposed as an indirect, biliary-mediated phenomenon driven by rapid weight loss and drug-induced gallbladder dysmotility via cholecystokinin (CCK) inhibition, with proactive biliary monitoring during the initial 24 weeks of therapy.

• Ocular disorders: Injection-site reactions and worsening of pre-existing diabetic retinopathy are relevant clinical concerns, with rare associations with nonarteritic anterior ischemic optic neuropathy reported primarily through pharmacovigilance and case-based evidence. Eye disorders were more frequently reported with semaglutide than liraglutide (ROR 2.67; 95% CI 1.54-4.63) and dulaglutide (ROR 1.89; 95% CI 1.30-2.75), with caution suggested when GLP-1 RAs are prescribed for patients characterized by ophthalmic vulnerability.

• Psychiatric outcomes and suicidality surveillance: There is no confirmed elevated risk of suicidality, but surveillance remains warranted. Suicidal ideation was disproportionately reported with semaglutide (ROR 6.49; 95% CI 1.57-26.81) and liraglutide (ROR 8.61; 95% CI 1.87-39.45) compared with dulaglutide. In children and adolescents with obesity or youth-onset type 2 diabetes, GLP-1 RA users had lower incidence and risk of suicidal ideation/behaviors (RD: -10.45, -14.54 to -6.36; HR: 0.11, 0.02 to 0.86) and depression (RD: -25.64, -34.90 to -16.39; HR: 0.37, 0.17 to 0.78) versus prevalent metformin users, with no difference in anxiety (RD: 5.95, -7.10 to 19.01; HR: 1.13, 0.69 to 1.84). In adolescents, GLP-1 RAs were associated with lower risk of suicidal ideation versus control (RR 0.73; 95% CI: 0.54-0.99; p = 0.046; I = 0%), with no significant effects on suicide attempts (RR 0.66; 95% CI: 0.16-2.61; p = 0.444; I = 0%) or depressive symptoms (RR 0.73; 95% CI: 0.36-1.48; p = 0.282; I = 50.4%).

• Renal, cardiovascular mortality, and other systemic signals: Associations with pancreatitis, medullary thyroid carcinoma, and acute kidney injury (AKI) have been reported primarily through pharmacovigilance and case-based evidence. Large-scale randomized trials, meta-analyses, and observational studies suggest that GLP-1RAs do not significantly increase AKI risk and may even confer renal benefits in high-risk populations. In individuals with obesity and without type 2 diabetes, GLP-1 RA treatment was associated with significantly lower risk of all-cause mortality (hazard ratio 0.23; 95% confidence interval 0.15-0.34) and several cardiovascular complications including ischaemic heart disease, heart failure, arrhythmias, hypertension, stroke and atrial fibrillation (all p < 0.05), and with lower risk of acute kidney injury and allergic reactions.

CagriSema's Landmark Weight Loss: Reshaping Obesity Treatment for Women

The recent announcement regarding CagriSema's performance in women with obesity or overweight marks a significant moment in the evolving landscape of weight management. Achieving an average weight loss of 25.0% at week 68 in women, with consistent efficacy across premenopausal (26.7%), perimenopausal (24.8%), and postmenopausal (23.1%) stages, positions this investigational therapy as a potential game-changer. This level of efficacy substantially surpasses that typically observed with GLP-1 receptor agonist monotherapies, which generally achieve weight reductions in the range of 12-17%.

The scientific basis for this enhanced efficacy lies in CagriSema's dual-agonist mechanism, combining the GLP-1 receptor agonist semaglutide with the amylin receptor agonist cagrilintide. Research indicates that this co-agonism engages distinct, complementary neural pathways, leading to greater suppression of both homeostatic and motivational aspects of feeding behavior than either monotherapy alone. This synergistic effect translates into superior weight loss and improved glycemic control compared to semaglutide or cagrilintide monotherapy, as evidenced by multiple meta-analyses and phase 2/3 trials.

Strategically, these results could enable CagriSema to establish a new benchmark for weight loss, potentially justifying a premium market position. The specific data in women, a demographic often seeking effective weight management solutions, allows for highly targeted clinical messaging and market penetration. However, the path forward is not without challenges. The high incidence of gastrointestinal adverse events, such as nausea and diarrhea, observed with CagriSema, though often mild-to-moderate, remains a key consideration for patient tolerability and long-term adherence. Furthermore, the anti-obesity market is intensely competitive, with other advanced incretin-based therapies demonstrating robust efficacy. While CagriSema shows marked superiority for achieving substantial weight loss (e.g., ≥20% body weight reduction), the absence of long-term cardiovascular outcomes data, a critical differentiator for established GLP-1RAs, could influence its broader adoption and reimbursement. Future development will need to balance these impressive efficacy signals with comprehensive safety and long-term benefit profiles to solidify CagriSema's position as a leading therapeutic option.